Payment overview · 2025
General Payments
$1,272.94
55 reported records · 16 companies
Healthcare provider profile · identity verified
Joseph M. Lavi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VALENCIA, CA · NPI 1912082017
Verified facts
What the public records show
CMS Open Payments records show Joseph M. Lavi, M.D. received $1,272.94 in general payments during 2025 across 55 reported records.
ABBVIE INC. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $202.69 | 15.9% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $196.61 | 15.4% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $157.57 | 12.4% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.93 | 12.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $120.77 | 9.5% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $109.11 | 8.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.77 | 7.7% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.41 | 4.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.15 | 2.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.19 | 2.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.94 | 1.9% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $22.95 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.76 | 1.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.61 | 1.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.84 | 1.4% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $17.64 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,272.94 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $183.53 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $182.68 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $165.64 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $120.77 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $112.64 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $109.11 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $101.63 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.66 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.66 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.71 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $51.41 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 132 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 203 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
203 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 508 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 502 | 136 |
| Losartan Potassium | Losartan Potassium | 401 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 359 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 99 |
| Lisinopril | Lisinopril | 311 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 82 |
| Metformin Hcl | Metformin Hcl | 264 | 77 |
| Simvastatin | Simvastatin | 252 | 67 |
| Trazodone Hcl | Trazodone Hcl | 244 | 58 |
| Lorazepam | Lorazepam | 223 | 45 |
| Ozempic | Semaglutide | 203 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 54 |
| Alprazolam | Alprazolam | 173 | 33 |
| Omeprazole | Omeprazole | 172 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 169 | 36 |
| Gabapentin | Gabapentin | 153 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 34 |
| Furosemide | Furosemide | 152 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 41 |
| Jardiance | Empagliflozin | 132 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 34 |
| Allopurinol | Allopurinol | 127 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 37 |
| Azithromycin | Azithromycin | 120 | 85 |
| Tramadol Hcl | Tramadol Hcl | 119 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 27 |
| Metformin Hcl Er | Metformin Hcl | 93 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 28 |
| Sertraline Hcl | Sertraline Hcl | 92 | 21 |
| Carvedilol | Carvedilol | 91 | 25 |
| Eliquis | Apixaban | 81 | 26 |
| Ibuprofen | Ibuprofen | 81 | 21 |
| Alendronate Sodium | Alendronate Sodium | 77 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 27 |
| Benazepril Hcl | Benazepril Hcl | 65 | 13 |
| Bupropion Xl | Bupropion Hcl | 64 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 13 |
| Glimepiride | Glimepiride | 62 | 19 |
| Temazepam | Temazepam | 58 | suppressed |
| Xarelto | Rivaroxaban | 58 | 17 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 23 |
| Potassium Chloride | Potassium Chloride | 56 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 16 |
| Montelukast Sodium | Montelukast Sodium | 53 | 13 |
| Atenolol | Atenolol | 51 | 14 |
| Meclizine Hcl | Meclizine Hcl | 49 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Pregabalin | Pregabalin | 44 | 14 |
| Valsartan | Valsartan | 44 | 12 |
| Meloxicam | Meloxicam | 43 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 14 |
| Methylprednisolone | Methylprednisolone | 40 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 12 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Baclofen | Baclofen | 38 | 14 |
| Mirtazapine | Mirtazapine | 38 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Famotidine | Famotidine | 33 | 15 |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Telmisartan | Telmisartan | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Naproxen | Naproxen | 31 | 11 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Prolia | Denosumab | 18 | 11 |
| Acyclovir | Acyclovir | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Tegretol Xr | Carbamazepine | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,272.94 · 55 records | ABBVIE INC. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, Flector, JARDIANCE, JATENZO, Kerendia, LEQVIO, Licart, MOUNJARO, NUZYRA, Ozempic, QULIPTA, REPATHA, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, TRINTELLIX, Tirosint, UBRELVY, VOQUEZNA, VOWST, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error